Editas Medicine Inc (NASDAQ: EDIT) kicked off on Monday, up 14.13% from the previous trading day, before settling in for the closing price of $2.76. Over the past 52 weeks, EDIT has traded in a range of $0.91-$5.85.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -1.48%. While this was happening, its average annual earnings per share was recorded 34.40%. With a float of $82.95 million, this company’s outstanding shares have now reached $83.71 million.
Let’s determine the extent of company efficiency that accounts for 246 employees. In terms of profitability, gross margin is 85.89%, operating margin of -590.68%, and the pretax margin is -805.8%.
Editas Medicine Inc (EDIT) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Editas Medicine Inc is 0.91%, while institutional ownership is 54.26%. The most recent insider transaction that took place on Jun 03 ’25, was worth 769. In this transaction SVP, Chief Financial Officer of this company sold 446 shares at a rate of $1.72, taking the stock ownership to the 17,506 shares. Before that another transaction happened on Jun 03 ’25, when Company’s EVP, CHIEF SCIENTIFIC OFFICER sold 726 for $1.72, making the entire transaction worth $1,252. This insider now owns 69,519 shares in total.
Editas Medicine Inc (EDIT) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.33 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 34.40% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 27.74% during the next five years compared to -1.48% drop over the previous five years of trading.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
Take a look at Editas Medicine Inc’s (EDIT) current performance indicators. Last quarter, stock had a quick ratio of 3.08. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.36.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.04, a number that is poised to hit -0.39 in the next quarter and is forecasted to reach -1.08 in one year’s time.
Technical Analysis of Editas Medicine Inc (EDIT)
Looking closely at Editas Medicine Inc (NASDAQ: EDIT), its last 5-days average volume was 2.85 million, which is a drop from its year-to-date volume of 3.06 million. As of the previous 9 days, the stock’s Stochastic %D was 43.98%.
During the past 100 days, Editas Medicine Inc’s (EDIT) raw stochastic average was set at 90.32%, which indicates a significant increase from 81.25% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.31 in the past 14 days, which was higher than the 0.19 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.11, while its 200-day Moving Average is $1.96.
